多发性骨髓瘤
免疫疗法
免疫系统
鉴定(生物学)
医学
受体
癌症研究
淋巴细胞亚群
免疫学
计算生物学
T细胞
生物信息学
生物
内科学
植物
作者
Michael Olson,Sabarinath Venniyil Radhakrishnan,Tim Luetkens,Djordje Atanackovic
标识
DOI:10.1016/j.clim.2018.10.006
摘要
The outcome of Multiple Myeloma (MM) patients has dramatically improved, however, most patients will still succumb to their disease. Additional therapeutic options are urgently needed and novel immunotherapies are enormously promising in the therapeutic armamentarium against MM. The first step in the development of any immunotherapy needs to be the identification of an appropriate target structure. In this review we present the current knowledge on surface molecule CD229, a member of the Signaling Lymphocyte Activation (SLAM) family of immune receptors. We believe that based on its characteristics, including (1) strong and homogenous expression on all myeloma cells, (2) expression on myeloma precursors, (3) absence from most normal tissues, (4) a central function in the biology of MM, CD229 (SLAMF3) represents a promising target for anti-MM immunotherapies. The introduction of novel anti-CD229 approaches into the clinic will hopefully lead to more durable responses, or maybe even cures, in MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI